- |
Ceritinib |
Zykadia® |
For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
Rapid Review complete |
22nd July 2015 |
|
- |
Cerliponase alfa |
Brineura® |
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. |
NCPE Assessment process complete |
26th March 2019 |
|
- |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review complete |
14th November 2019 |
|
- |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe rheumatoid arthritis. |
NCPE Assessment Process complete |
2nd September 2010 |
|
23049 |
Chlormethine gel |
Ledaga® |
Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. |
Rapid Review Complete |
20th September 2023 |
|
22033 |
Cholecalciferol |
Egostar® |
Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
Rapid Review complete |
23rd June 2022 |
|
21062 |
Cholic acid |
Orphacol® |
For the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years, and adults. |
Rapid Review complete |
12th January 2022 |
|
- |
Ciclosporin |
Ikervis® |
For the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes. |
Rapid Review complete |
18th January 2016 |
|
22021 |
Ciltacabtagene autoleucel |
Carvykti® |
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
27th September 2023 |
|
- |
Cladribine |
Mavenclad® |
For the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features |
NCPE Assessment process complete |
20th July 2018 |
|
- |
Clindamycin 1% with tretinoin 0.025% |
Treclinac® |
For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. |
Rapid Review complete |
7th May 2014 |
|
19045 |
Co-enzyme Q10 |
CoQun® eye drops |
As a complementary add-on treatment to antihypertensive glaucoma therapy. |
Rapid Review complete |
13th January 2020 |
|
- |
Cobimetinib |
Cotellic® |
For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
NCPE Assessment process complete |
5th January 2017 |
|
- |
Colesevelam |
Cholestagel® |
Hypercholesterolaemia |
Rapid Review complete |
22nd October 2010 |
|
- |
Colistimethate sodium |
Colobreathe® |
For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. |
Rapid Review complete |
28th June 2013 |
|
- |
Collagenase Clostridium Histolyticum |
Xiapex® |
Treatment of Dupuytren’s contracture in adult patients with a palpable cord. |
Rapid Review complete |
9th June 2011 |
|
21017 |
Conestat alfa |
Ruconest® |
For the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. |
Rapid Review complete |
2nd June 2021 |
|
- |
Corifollitropin alfa |
Elonva® |
Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. |
Rapid Review complete |
22nd October 2010 |
|
- |
Crizotinib |
Xalkori® |
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting) |
NCPE Assessment process complete |
27th August 2013 |
|
- |
Crizotinib |
Xalkori® |
For the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
- |
Crizotinib |
Xalkori® |
For the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
- |
Cysteamine bitartrate delayed-release |
Procysbi® |
For the treatment of proven nephropathic cystinosis. |
NCPE Assessment process complete |
15th November 2017 |
|
23063 |
Cytisine |
Citidaron® |
Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
Rapid Review Complete |
28th November 2023 |
|
- |
Dabigatran |
Pradaxa® |
For the prevention of stroke and systemic embolism in atrial fibrillation |
NCPE Assessment Process Complete |
3rd June 2011 |
|
- |
Dabigatran |
Pradaxa® |
For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery. |
NCPE Assessment Process Complete |
1st September 2008 |
|
- |
Dabigatran |
Pradaxa® |
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. |
NCPE Assessment Process Complete |
13th June 2014 |
|
- |
Dabrafeib |
Tafinlar® |
For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
NCPE Assessment Process Complete |
24th June 2014 |
|
- |
Dabrafenib |
Tafinlar® plus Mekinist® |
In combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. |
NCPE Assessment Process Complete |
19th August 2020 |
|
- |
Daclatasvir |
Daklinza® |
In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4) |
NCPE Assessment Process Complete |
29th May 2015 |
|
- |
Daclizumab |
Zinbryta® |
Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis. |
Rapid review complete |
23rd November 2016 |
|
- |
Dacomitinib |
Vizimpro® |
Indicated as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. |
Rapid review complete |
13th May 2019 |
|
- |
Dalbavancin |
Xydalba® |
Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. |
Rapid review complete |
28th April 2017 |
|
- |
Dapagliflozin |
Forxiga® |
Indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
31st December 2013 |
|
22030 |
Dapagliflozin |
Forxiga® |
Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
Rapid review complete |
14th March 2024 |
|
22040 |
Dapagliflozin |
Forxiga® |
For the treatment of chronic kidney disease |
Rapid review complete |
14th July 2022 |
|
23065 |
Dapagliflozin |
Forxiga® |
Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%. |
Rapid Review Complete |
14th March 2024 |
|
- |
Daratumumab |
Darzalex® |
For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
13th March 2017 |
|
- |
Daratumumab |
Darzalex® in combination with bortezomib and dexamethasone |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
15th March 2019 |
|
- |
Daratumumab in combination with lenalidomide and dexamethasone |
Darzalex® |
For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy. |
Rapid review complete |
27th November 2017 |
|
20025 |
Daratumumab |
Darzalex® |
In combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. |
NCPE Assessment Process Complete |
16th November 2021 |
|
21041 |
Daratumumab |
Darzalex® in combination with cyclophosphamide, bortezomib and dexamethasone |
For the treatment of adult patients with newly diagnosed systemic light chain amyloidosis. |
NCPE Assessment Process Complete |
19th December 2022 |
|
22039 |
Daratumumab |
Darzalex® |
In combination with lenalidomide (Revlimid®) and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant |
NCPE Assessment Process Complete |
20th September 2023 |
|
20022 |
Darolutamide |
Nubeqa® |
For the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. |
NCPE Assessment Process Complete |
10th September 2021 |
|
- |
Darunavir & cobicistat |
Rezolsta® |
Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. |
Rapid review complete |
8th January 2015 |
|
- |
Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide |
Symtuza® |
For the treatment of HIV-1 in adults and adolescents. |
Rapid review complete |
26th October 2017 |
|
- |
Darvadstrocel |
Alofisel® |
For the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn’s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula. |
NCPE Assessment Process Complete |
24th September 2019 |
|
- |
Decitabine |
Dacogen® |
For AML in patients who are >65yrs who are not candidates for standard induction therapy |
Rapid review complete |
21st December 2012 |
|
22019 |
Defatted powder of Arachis hypogaea L., semen (peanuts) |
Palforzia® |
For the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet. |
NCPE Assessment Process Complete |
29th November 2023 |
|
- |
Defibrotide |
Defitelio® |
Indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy |
Rapid review complete |
15th July 2014 |
|
- |
Degarelin |
Firmagon® |
For the treatment of prostate cancer |
Rapid review complete |
15th October 2009 |
|